Genitourinary Cancer
Key clinical trial data in urothelial carcinoma at ASCO 2021
Chemotherapy is central to the treatment of advanced or metastatic urothelial carcinoma (UC), and platinum-based treatments, like cisplatin, have been…
Date: 10th September 2021
Prostate Cancer Highlights from ASCO 2021 with Pedro Barata
This year, at the American Society of Clinical Oncology (ASCO) Virtual Meeting 2021, experts came together virtually to present and…
Date: 23rd August 2021
The GU Cancer Sessions: Bladder and Kidney Highlights from ASCO 2021
During the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting, an exciting array of advances in genitourinary (GU) cancer…
Date: 18th August 2021
EAU 2021: updates in testicular cancer
Whilst advances in diagnostic procedures, radiotherapies, cisplatin-based chemotherapy, and surgery have meant that testicular cancer is curable in around 95%…
Date: 28th July 2021
ASCO 2021: PSMA-targeted radionuclide therapy for prostate cancer
Prostate-specific membrane antigen (PSMA) is overexpressed in more than 80% of prostate cancer tumors, making it a promising diagnostic and…
Date: 25th June 2021
Latest news in GU: CAR-T in RCC, updates from IMvigor130, & liquid biopsies in prostate cancer
The American Association for Cancer Research Annual Meeting 2021 (AACR) took place virtually this year and showcased an array across…
Date: 13th May 2021
Bladder cancer: advances in the spotlight and what these mean for therapy
Over the past few years, the field of bladder cancer has seen an array of exciting clinical advancements, ranging from…
Date: 16th August 2018
